Jane Street
ABUS icon

Jane Street’s Arbutus Biopharma ABUS Stock Holding History

Jane Street’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$149K Buy
33,000
+22,800
+224% +$99.7K ﹤0.01% 10393
2025
Q4 		$49.1K Sell
10,200
-13,800
-58% -$62.1K ﹤0.01% 10516
2025
Q3 		$109K Sell
24,000
-3,700
-13% -$13.6K ﹤0.01% 10099
2025
Q2 		$85.6K Sell
27,700
-28,200
-50% -$93.6K ﹤0.01% 9016
2025
Q1 		$195K Buy
+55,900
New +$186K ﹤0.01% 8471
2023
Q1 		– Sell
-25,500
Closed -$59.4K – 8907
2022
Q4 		$59.4K Hold
25,500
– – ﹤0.01% 8305
2022
Q3 		$49K Sell
25,500
-7,600
-23% -$17.9K ﹤0.01% 8934
2022
Q2 		$90K Sell
33,100
-94,100
-74% -$241K ﹤0.01% 8696
2022
Q1 		$379K Sell
127,200
-101,600
-44% -$311K ﹤0.01% 7977
2021
Q4 		$890K Buy
228,800
+177,000
+342% +$688K ﹤0.01% 6134
2021
Q3 		$222K Buy
+51,800
New +$173K ﹤0.01% 8700
2021
Q2 		– Sell
-60,100
Closed -$200K – 9681
2021
Q1 		$200K Sell
60,100
-92,600
-61% -$357K ﹤0.01% 8266
2020
Q4 		$542K Buy
+152,700
New +$535K ﹤0.01% 5605

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Jane Street's ABUS Position: Q1 2026 in Review

Jane Street sold out of Arbutus Biopharma (ABUS) in Q1 2026, closing a stake of 83,933 shares — an estimated $367K sold.

Jane Street first reported a position in ABUS in Q1 2014 and held it in 27 quarters. The position peaked at $1.37M in Q4 2021. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Jane Street reported no remaining Arbutus Biopharma position as of Q1 2026 after selling out during the quarter.
  • Jane Street sold 83,933 Arbutus Biopharma shares in Q1 2026, an estimated $367K.
  • Jane Street first reported a position in Arbutus Biopharma in Q1 2014 and held it in 27 quarters.
  • Jane Street's Arbutus Biopharma position peaked at $1.37M in Q4 2021.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.